Macedonia’s Alkaloid relies on strong product portfolio to fuel robust expansion
Alkaloid closed 2011 with a 7.0% rise in its consolidated profit. What are the main factors for being profitable and successful?
I remember back in 2005, when I was a director of Alkaloid’s PC Pharmaceuticals, we set a team goal for achieving total sales of 100 million euro, which from that perspective seemed unreachable. Now, I am pleased to say that in 2011, at the company’s 75th anniversary, we achieved consolidated sales of some 110 million euro, which is an annual growth of 14% and a double increase over 2005. Last year, Alkaloid’s sales on the domestic market rose by 12% while consolidated exports increased by more than 14% to over 64.1 million.
Our success is based mainly on the quality of our products, the high-quality staff we have, the brand of Alkaloid as well as individual product brands that have been built for years by the generations before us. During my fiveyear CEO mandate, Alkaloid remained consistent in pursuing the goals of maintaing the tendency of growth on the domestic and export markets, finding a balance between growth and liquidity, strengthening the market positions, expansion of product portfolio and building new partnerships and new forms of cooperation.
Alkaloid’s portfolio includes teas and cosmetics. Which segments of operations are you focused on? What will be your development priorities?
Pharmaceuticals is our main business segment into which most of our investments flow. Alkaloid’s drug portfolio contains over 140 types of products and over 344 pharmaceutical forms. The leading pharmaceutical brand is Caffetin, which this year marks 55 years of existence, and which, according to many criteria, is one of the leading Macedonian export brands.
With over 10 billion tablets sold so far, Caffetin has become a synonym for a pain-killer. Consumer awareness of the brand urged Alkaloid to develop new product extensions for new indications. The first in the line was Caffetin Cold, followed by Caffetin menstrual and Caffetin Cold with natural vitamin C. The latest, non-tablet extension is designed for cold and flu indications, Caffetin Cold-max bags powder whose development has been worked out for three years in cooperation with a foreign partner.
The OTC line, the cardiac medications, drugs that act on the central nervous system and cephalosporin antibiotics are the four main lines on which the company's growth strategy is based. We also pay special attention to the expansion of our product portfolio with new, efficient, safe, high-quality and priceaffordable drugs from our own production line or through licensed collaborations. The list of global pharmaceutical companies that have chosen Alkaloid as proven and reliable partner, is constantly expanding.
Botanicals is another complementary seg-